RNXT · RENOVORX INC
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
2570 West El Camino Real, Mountain View, CA, 94040, United States
Biotechnology
Healthcare
Market Cap
71.3M
52 Wk Range
$0.70 - $2.59
Previous Close
$1.55
Open
$1.57
Volume
269,370
Day Range
$1.55 - $1.61
Enterprise Value
64.47M
Cash
9.479M
Avg Qtr Burn
-2.867M
Insider Ownership
3.60%
Institutional Own.
20.38%
Qtr Updated
Jun 30th 2026